Biotech / Medical | Biotech News


Previous 10 | Next 10 
To: Jibacoa who wrote (6554)6/26/2009 4:25:11 PM
From: Jibacoa   of 7042
 
ZURICH (Reuters) – Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday.

Biosimilars are viewed as a promising new market, given the pent-up demand for cheaper versions of extremely expensive biotech drugs, some of which are coming to the end of their patent life.

Somatropin, made by Novartis' generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner's syndrome or chronic renal insufficiency, the group said.

The approval is for the same range of diseases as the reference product, Pfizer Inc's Genotropin, Novartis said. The drug is already approved in Europe and the United States as Omnitrope.

Biotech drugs, used to treat everything from cancer to autoimmune diseases such as rheumatoid arthritis, tend to be more expensive and complex than traditional chemical medicines because they are made from living cells.

Conventional drugs can lose up to 90 percent of their sales within a year once they face generic competition. But relatively few companies are now capable of making biosimilars.

Brand-name biotech companies such as Roche Holding AG's Genentech Inc and Amgen Inc say they need an adequate period without competition to encourage development of new medicines.

Novartis shares fell 1.0 percent to 45.04 Swiss francs by 0827 GMT (4:27 a.m. EDT), in line with the DJ Stoxx European healthcare index.

The first biosimilars have already been approved and are on the market in Europe. The United States, the world's biggest and most lucrative pharmaceuticals market, is still discussing a regulatory pathway for follow-on biotech treatments.

Drugs industry supplier Lonza Group Ltd believes it is tough to predict the size of the market because of uncertainty of how regulations will end up, its chief executive Stefan Borgas said earlier this month.

"I think common wisdom at the moment is that the global biologics market is something like $80-90 billion, and what the price reduction will be is a bit of a crystal ball discussion at the moment," Borgas told Reuters.

"Even if the most optimistic forecast is too optimistic, it will be a significant market. In the billions and the 10s of billions."

Share Recommend | Keep | Reply | Mark as Last Read

From: sim16/29/2009 11:09:47 PM
1 Recommendation   of 7042
 
Wall Street reporter’s inaccurate reports are becoming patient safety issue claims biomedical company CEO

Written by M.E.Garza

Monday, 29 June 2009 03:49

Responding to investor concerns that TheStreet.Com has continued targeting thriving small-cap biomedical companies with inaccurate articles, BioMedReports has been repeatedly contacted by officials of publicly traded companies-- among them, Hoji Alimi who serves as CEO of Petaluma, California based Oculus Innovative Sciences (NASDAQ:OCLS).

Mr. Alimi’s breakthrough Microcyn® Technology- a water based, biocompatible solution used increasingly around the world to help prevent and treat infections in chronic and acute wounds- has been gaining attention both on Wall Street and in the national media due to its rapid kill anti-microbial and healing properties.

A San Francisco bay area television station recently reported that the technology is a promising path to a major medical advance and earlier this month, Oculus shares rose after the company received an expanded 510(k) label clearance from the U.S. Food and Drug Administration (FDA) to market it’s Microcyn® Skin and Wound Cleanser with preservatives as both a prescription and over-the-counter formulation. The new prescription product is indicated for use by health care professionals to manage the debridement of wounds such as stage I-IV pressure ulcers, diabetic foot ulcers, post-surgical wounds, first- and second-degree wounds, grafted and donor sites.

Not long after the announcement, TheStreet.Com’s biomedical columnist Adam Feuerstein leveled an accusation that Oculus “appeared to be skirting U.S. drug laws by claiming that its wound-cleansing product containing common diluted bleach has drug-like therapeutic properties.”

Calls from angry and confused patients, doctors and investors flooded the offices of the company and shares were negatively impacted. It certainly wasn’t the first time, TheStreet.Com’s coverage has impacted a stock's price and its shareholders, but company officials became concerned when they heard reports that members of the medical community and patients who use Microcyn® products were adversely affected by the report.

“This is becoming a patient safety issue and putting public safety at risk,” Alimi told BioMedReports in an exclusive recorded interview. “It’s no longer [about] attacking a company and the market potential and market cap. You’re damaging public safety.”

Alimi, was concerned enough to craft a letter to CNBC’s Jim Cramer who co-founded TheStreet.com in 1996 and took the company public in 1999.

“[I] copied the gentleman [Feuerstein] who had written the report, “explained the Iranian-born, Alimi. While the Oculus CEO made it clear that he believed the publication and writer were entitled to their constitutionally protected opinion he felt that the publication had fallen short of reporting the truth and science behind the technology accurately.

“When you haven’t done your due diligence and you don’t understand the basic chemistry of our product [and] you make recommendations like that you are putting patients’ safety at risk,” insists Alimi. “There has to be a level of integrity in the research written and I think that’s really lacking in their case.”

Last month, Dr. William A. Carter, the CEO of Hemispherx Biopharma (NASDAQ:HEB) angrily reacted to slanted attacks and base-less reports by stating that “Adam Feuerstein wouldn’t know good science if it bit him in the ass.”

Investors across the internet have also lashed out against Feuerstein’s coverage on message boards - many of them leveling threats of physical violence while others have called for investigations by federal authorities and even lawsuits. Feuerstein has responded to some of the anger by stating that “Carter's bluster [was] designed to divert attention away from the real matter at hand” and by clarifying to his reader that he writes his columns and stories when he uncovers information that he thinks is important for investors to have.

Recently, Thomas Clarke, who had served as CEO of the financial news website, announced that he was leaving the publicly traded company “effective immediately.” It was reported that Clarke’s abrupt departure came less than a day after Jon Stewart’s Comedy Central cable hit, The Daily Show, aired tape of Jim Cramer explaining in a Street.com webcast how he, as a hedge fund manager, manipulated value to serve some publicly traded companies and investors at the expense of others.

Stewart’s show took Cramer, CNBC, and financial “journalism,” in general, to the cleaners but Feuerstein has insisted and written: “I don't make this job personal. I like to find good stories to write about -- stories that hopefully help investors make some money in biotech. (The best way to do that, sometimes, is to avoid buying certain stocks) If the stories are controversial, it's all the better, because those are usually the most fun.”

In the case of Oculus, the “story” has definitely not been perceived as “fun” and appears to fall short of fact- scientific or otherwise- according to Alimi.

Bleach is sodium hypochlorite which is anti-microbial at a high pH (pH scale of 8 and higher).

“When you take that solution to a lower pH, you no longer have sodium hypochlorite as your active [ingredient], you have Hypochlorus acid (HOCI)” explains Alimi. “It’s a different chemistry. And Hypochlorus acid can be converted to different chemicals in a wound depending on how it’s manufactured, so that is a significant difference in the chemistry of our product.”

Alimi points out that when a physician uses bleach in a wound, he will surely kill the infection in that wound, but he will also kill tissue and cause harm in the wound bed. In addition, diluted bleach solutions have not shown any wound healing impact- something that independent medical studies and trials have attributed to Microcyn®.

Some feel that this type of reporting can be directly blamed for TheStreet’s continued troubles and decline in the current bear market.

As recently reported, the publication’s stock recently dropped below $2 per share, down from $9.50 per share a year ago. In recent years it had traded as high as $16 per, but it has also suffered with the decline in the media and advertising markets as well as a major purge of subscriber newsletter operations. Its success was initially tied closely to Mr. Cramer’s popularity, but the recent heavy criticism may finally be reflecting in the company’s (NASDAQ:TSCM) stock price performance.

In a strange twist, many have noted that stocks which have been the subject of slanted reports by Mr. Feuerstein, have just been added to the Russell 3000 index while TSCM itself has been booted as a financial services sector stock.

An excerpt of Mr. Almi’s interview with BioMedReports can be heard below. In it, he reacts to investors’ questions about litigation, TheStreet.Com’s coverage and whether or not Oculus has considered issuing additional common shares.


biomedreports.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: sim1 who wrote (6556)6/30/2009 4:09:45 AM
From: DewDiligence_on_SI   of 7042
 
The author of that "article" in BiomedReports.com is a con man and the website itself is pump & dump operation*.

Please do not post anything from that site on this board again.

*Examples:

investorshub.advfn.com 

investorshub.advfn.com 

investorshub.advfn.com 

...and many others.

Share Recommend | Keep | Reply | Mark as Last Read

From: tnsaf6/30/2009 12:24:52 PM
   of 7042
 
Jury awards Centocor $1.7B in patent case against Abbott

Centocor Ortho Biotech Inc. said late Monday that a federal jury has awarded the company $1.67 billion in a patent infringement case against Abbott Laboratories.

Horsham, Pa.-based Centocor, a division of Johnson & Johnson (NYSE:JNJ), makes the blockbuster rheumatoid arthritis treatment Remicade, and had sued Abbott over Abbott’s arthritis drug, Humira. Both are so-called anti-TNF arthritis treatments.

Horsham, Pa.-based Centocor said it is the exclusive licensee of the patent, which is co-owned by New York University.

Centocor President Kim Taylor said “the jury recognized our valuable intellectual property, finding our patent both valid and infringed. We will continue to assert intellectual property rights for our immunology therapies, as they offer significant advances in treatment for patients with a number of immune mediated inflammatory diseases.”

An Abbott representative could not be immediately reached for comment.

Reports said Illinois-based Abbott is planning to appeal.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: tnsaf who wrote (6558)7/1/2009 4:49:50 PM
From: Jibacoa   of 7042
 
WASHINGTON (Reuters) – Researchers have identified the early master cells that make up the human heart and said on Wednesday they could someday be used to make patches to fix damaged hearts.

The discovery, published in the journal Nature, also sheds surprising light on how human hearts develop in the womb, and how congenital heart disease develops.

"This cell that we describe is probably not going to be used directly as cell-based therapy because it has the possibility of going into too many different cell types," said Kenneth Chien of the Harvard Stem Cell Institute and Massachusetts General Hospital.

But Chien said his team is now looking for intermediate cells that are on their way to becoming beating heart muscle, the cells that line the arteries, and other heart cell types.

More immediately, it helps in understand what causes heart disease, Chien told reporters in a telephone briefing.

"The study provides a new way of understanding heart disease as it appears in children and in adults," Chien said.

Chien's team worked entirely with human cells and found the human heart develops differently from hearts in mice -- a surprising finding.

"The human heart at birth is more than a thousand times bigger than the adult mouse heart, yet the size of the initial embryos are close in size. Humans are just a heck of a lot bigger than mice, and every organ is bigger. How is that achieved?" Chien asked.

EARLY HEART STEM CELLS

In mice, the progenitor cells that Chien's team found exist for just 48 hours. But a mouse develops from conception to birth in just three weeks, while humans gestate for nine months.

And it turns out the human heart develops from patches of these early heart stem cells. Another surprise -- these patches of stem cells tend to congregate in areas linked with congenital heart disease, including the heart valves and pumping chambers.

"Congenital heart disease may be a stem cell disease," Chien said. Congenital heart disease affects up to 2 percent of newborns and often requires surgery within days or weeks of birth.

Chien does not believe it would be possible to grow entire hearts using the cells -- too complicated -- but it may be possible to grow patches to fix areas damaged by heart attacks, or faulty valves, he said.

Batches of cells could also be used to test drugs for possible unexpected side-effects on the heart.

"Finding a cell that can make all the parts of the heart, including the contracting muscle, the smooth muscle and the vessels, brings us much closer to the possibility of repairing human hearts with new cells," Dr. Doug Melton, who helps direct the stem cell institute, said in a statement.

Stem cells are the body's master cells, the source of all cells and tissue in the body. Chien's team worked with embryonic stem cells, which are found in days-old embryos and which at first can give rise to every cell type.

These cells differentiate as an embryo develops, becoming destined for certain fates as heart cells, nerve cells and so on. Using human embryonic stem cells is controversial as some people object to destroying a human embryo.

Some groups have managed to turn ordinary skin cells into stem cells. They are called induced pluripotent stem cells or iPS calls and Chien wants to try and turn iPS cells into the heart progenitor cells -- but says working with true human embryonic stem cells is important.

Banks of human heart progenitor cells might be grown and used for treatments eventually, he said, especially if they can be matched to all the different human tissue and blood types.

Share Recommend | Keep | Reply | Mark as Last Read

From: tnsaf7/1/2009 11:41:01 PM
   of 7042
 
Down to the bone
Posted by Elie Dolgin
[Entry posted at 29th June 2009 03:52 PM GMT]
the-scientist.com 

A fusion protein that ferries a healthy version of a bone-related enzyme gone awry has shown early clinical success in treating a rare bone disorder with no known therapy, researchers reported earlier this month at the Endocrine Society's annual meeting in Washington, DC. The drug -- which is essentially a protein-based enzyme delivery mechanism -- could open the door to treatments of other skeletal disorders that have so far been deemed untreatable.

Radiographic signs of childhood (left)
and adult (right) hypophosphatasia
Image: NIH


"This is probably the most promising approach so far" for metabolic bone disorder therapies, Sundeep Khosla, an endocrinologist at the Mayo Clinic in Rochester, Minn., who was not affiliated with the work, told The Scientist.

The new therapy targets a rickets-like disease called hypophosphatasia (HPP), which is caused by a single mutation in the gene coding for an enzyme known as tissue non-specific alkaline phosphatase, or TNSALP. Developed by Enobia Pharma, a biotech company in Montreal, Canada, it is based on a fusion protein that contains the active portion of TNSALP merged with a small acidic peptide chain that targets the drug to bone, the site of enzymatic activity. In healthy people, TNSALP is normally tethered to the outside of bone- and cartilage-forming cells where it breaks down phosphate. But in HPP patients, the enzyme doesn't fold properly, which leads to a build up of several phosphate-containing compounds in blood and urine, and produces a range of clinical symptoms including softer bones, shorter limbs, respiratory problems, premature tooth loss, and often infant death.

Michael Whyte, a medical researcher at Washington University's School of Medicine in St Louis, Missouri, who consults for Enobia, announced the results of a Phase I trial involving afflicted adults and an ongoing efficacy trial in severely-affected HPP infants. In both studies, patients took to the medication well, and the first two infants to receive regular doses of the drug showed substantial bone mineralization and improved breathing abilities, Whyte reported at the meeting.

Enobia came up with the fusion construct in 2005. At the time, the company was working on a similar delivery vehicle to treat X-Linked Hypophosphatemic Rickets (XLH), a disease closely related to HPP that is also caused by a single aberrant enzyme. The XLH therapy, however, wasn't effective in a mouse model of the disease. They then switched to HPP and the enzyme replacement therapy "worked right from the first experiment," said Philippe Crine, Enobia's chief scientific officer. "It was really spectacular." Crine doesn't know exactly why the drug platform worked for one disease and not the other, but he is confident that the same bone-targeting technology should be effective in treating other related bone disorders.

In the past, clinicians have tried several approaches to tackling HPP, including vitamin D supplements and bone marrow transplants, but all these therapies failed. Researchers also injected TNSALP intravenously, but again with no success; the infused enzyme "kind of gets into the bloodstream, but it goes all over the place," said Khosla. "Being able to actually target therapeutic compounds to bone just hasn't been easy. Part of technical problem has been finding the right carriers, and [Enobia] seems to have found one."

Last year, a team led by Whyte, Crine, and José Luis Millán, a molecular geneticist at the Burnham Institute for Medical Research in La Jolla, Calif., published preclinical results showing that subcutaneous injections of their fusion protein drug mopped up phosphates floating in the blood and significantly improved survival and bone formation in knockout mice with a severe human infant-like form of HPP.

Enobia and its partners are now investigating the efficacy of different doses of the medication in their mouse models, as well as letting the mice develop for a couple of weeks before administering the drug, instead of treating them directly after birth. This is important because humans with the rare disorder often go months or years before being properly diagnosed. Early results show that the late-treated mice also have improved bone function and live longer, although not to the same extent as mice given the drug right away. "The bottom line," said Millán, "is that treatment is good even if conferred very late."

The drug -- which is being manufactured by Princeton, NJ-based Laureate Pharma -- was granted an orphan drug designation by the US Food and Drug Administration last October, and a fast track designation in May to help speed along its clinical development. The company plans to start Phase II adult trials later this summer.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

From: Biotech Jim7/2/2009 7:49:43 AM
   of 7042
 
FDA gives black box for Chantix (varenecline) and Zyban (buproprion).

finance.yahoo.com 

Not good news for OREX and one of its obesity combo meds in development.

BJ

Share Recommend | Keep | Reply | Mark as Last Read

From: Doc Bones7/2/2009 12:23:32 PM
1 Recommendation   of 7042
 
Ban Is Advised on 2 Top Pills for Pain Relief [NYT]

It's not mentioned in the article, but I believe that the DEA prefers that opiates be mixed with acetaminophen. The idea is that people won't be able to take too much of the opiates because of the side effects from the acetaminophen, so the pills won't be attractive to addicts. I know Vicodin at least does not require a triplicate prescription [one copy going to the DEA.]

Perhaps having drug mixes determined by the DEA is not a great idea.

Doc


By GARDINER HARRIS
Published: June 30, 2009

ADELPHI, Md. — A federal advisory panel voted narrowly on Tuesday to recommend a ban on Percocet and Vicodin, two of the most popular prescription painkillers in the world, because of their effects on the liver.

The Takeaway With Donald G. McNeil Jr.The two drugs combine a narcotic with acetaminophen, the ingredient found in popular over-the-counter products like Tylenol and Excedrin. High doses of acetaminophen are a leading cause of liver damage, and the panel noted that patients who take Percocet and Vicodin for long periods often need higher and higher doses to achieve the same effect.

Acetaminophen is combined with different narcotics in at least seven other prescription drugs, and all of these combination pills will be banned if the Food and Drug Administration heeds the advice of its experts. Vicodin and its generic equivalents alone are prescribed more than 100 million times a year in the United States.

Laureen Cassidy, a spokeswoman for Abbott Laboratories, which makes Vicodin, said, “The F.D.A. will make a final determination and Abbott will follow the agency’s guidance.”

The agency is not required to follow the recommendations of its advisory panels, but it usually does.

The panel’s 20-17 vote to recommend a ban on the combination drugs was one of 11 it took at a meeting called to advise the F.D.A. on problems arising from the extraordinary popularity of acetaminophen. In 2005, American consumers bought 28 billion doses of products containing the ingredient.

While the medicine is effective in treating headaches and reducing fevers, even recommended doses can cause liver damage in some people. And more than 400 people die and 42,000 are hospitalized every year in the United States from overdoses.

In hopes of reducing some of these accidents, the committee voted 24 to 13 to recommend that the F.D.A. reduce the highest allowed dose of acetaminophen in over-the-counter pills like Tylenol to 325 milligrams, from 500. And members voted 21 to 16 to reduce the maximum daily dosage to less than 4,000 milligrams.

But they voted 20 to 17 against limiting the number of pills allowed in each bottle, with members saying such a limit would probably have little effect and could hurt rural and poor patients. Bottles of 1,000 pills are often sold at discount chains.

“We have no data to show that people who overdose shop at Costco,” said Dr. Edward Covington, a panel member from the Cleveland Clinic Foundation.

Dr. Lewis S. Nelson, a toxicologist from the New York University School of Medicine who served as the panel’s acting chairman, said experts had been warning of the dangers of combination painkillers like Percocet, which is made by Endo Pharmaceuticals, and Vicodin for years.

Still, the recommendation is likely to come as a shock to many patients, who may be unaware of the dangers of high doses of acetaminophen — even if they know the drugs contain the ingredient.

Some doctors already avoid prescribing pills that combine acetaminophen with narcotics like oxycodone (found in Percocet) and hydrocodone (in Vicodin).

“It ties the doctor’s hands when you put the two drugs together,” said Dr. Scott M. Fishman, a professor of anesthesiology at the University of California, Davis, and a former president of the American Academy of Pain Medicine. “There’s no reason you can’t get the same effect by using them separately.”

Dr. Fishman said the combinations were prescribed so often for the sake of convenience, but added, “When you’re using controlled substances, you want to err on the side of safety rather than convenience.”

Still, some doctors predicted that the recommendation would put extra burdens on physicians and patients.

“More people will be suffering from pain,” said Dr. Sean Mackey, chief of pain management at Stanford University Medical School. “More people will be seeing their doctors more frequently and running up health care costs.”

In a statement, Johnson & Johnson, Tylenol’s maker, said it “strongly disagrees” with the proposed restrictions on acetaminophen, adding that they would be likely to “lead to more serious adverse events as consumers shift to other over-the-counter products,” like Advil and aspirin.

Linda A. Suydam, president of the Consumer Healthcare Products Association, said the committee had ignored studies showing that doses sold by her members — two pills of 500 milligrams, up to four times a day — were safe. “I think this is a very effective dose and one needed for individuals who experience chronic pain,” she said.

The committee also turned its attention to over-the-counter children’s medicines containing acetaminophen, voting 36 to 1 to limit them to a single formulation. Right now the liquids are sold in two different concentrations, leading to confusion among doctors and parents.

“I don’t think it’s safe to have two formulations out there,” said Dr. Nelson, the acting chairman.

The members were divided over which formula to recommend, the concentrated or the less concentrated one. F.D.A. officials suggested that they would likely settle on the less concentrated formula so that if parents make a mistake, they would be less likely to overdose.

Acetaminophen is included in a vast array of over-the-counter cough and cold products, including Nyquil, Excedrin and many others. A small share of accidental poisonings result when people take two or more of these combination products without understanding the risk.

The F.D.A. asked the committee whether it should ban combination products that include acetaminophen. The vote was 24 to 13 against such a ban, with many members saying consumers saw the products as valuable.

“Based on the data provided, the combination O.T.C. medications really contributed very little to overall poisonings,” said Dr. Osemwota A. Omoigui, a panel member from the Los Angeles Pain Clinic.

A 2005 study found that most poisonings resulted from patients’ taking Vicodin and similar products that combine a narcotic with acetaminophen.

“I think this is the one place where we can engineer in safety,” said Dr. Judith M. Kramer, a panel member and an associate professor of medicine from Duke University Medical Center who voted to ban the combination prescription medicines. “We’re here because there are inadvertent overdoses that are fatal, and this is our one opportunity to have a big impact.”

Consumers need to be better educated about the risks of popular medicines, most panel members agreed.

“If you keep track of what you’re taking, none of this is an issue for you,” Dr. Jan Engle, a panel member and head of the Department of Pharmacy Practice at the University of Illinois in Chicago, said in an interview after the meeting.

Donald G. McNeil Jr. contributed reporting from New York.

nytimes.com 

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)

To: tnsaf who wrote (6560)7/2/2009 1:10:12 PM
From: Doc Bones   of 7042
 
"the gene coding for an enzyme known as tissue non-specific alkaline phosphatase, or TNSALP"

a story on TNSALP, posted by tnsaf

.... hmmmm

;-)

Doc@thereAREnocoincidences.com

Share Recommend | Keep | Reply | Mark as Last Read

To: Doc Bones who wrote (6562)7/2/2009 1:48:17 PM
From: software salesperson   of 7042
 
Doc,

there's another reason as well:

Combining an opioid such as hydrocodone [ i.e. vicodin ] with another analgesic [ e.g. acetaminophen ] can increase the effectiveness of the drug without increasing opioid-related side effects (e.g., nausea, constipation, sedation).

sales

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2013 Knight Sac Media. All rights reserved.